SciELO - Scientific Electronic Library Online

 
vol.21 issue2Procedures Manual for hospital wards where clinical trials are executedEffectiveness of the treatment with oleozón versus aloe cream in the subprosthesis stomatitis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Archivo Médico de Camagüey

On-line version ISSN 1025-0255

Abstract

GONZALEZ REIGADA, Alicia et al. Therapeutic answer in patients who suffers from polycystic ovary syndrome. AMC [online]. 2017, vol.21, n.2, pp. 191-201. ISSN 1025-0255.

Background: polycystic ovary syndrome is an heterogeneous disorder; it has been recognized as the main cause of infertility on women during reproductive ages. Objective: to determine the therapeutic answer on patients who suffers from polycystic ovary syndrome in Camaguey during January 2013 to January 2015. Methods: an observational descriptive and longitudinal study was carried out. The universe was sample by all patients who were diagnosed with polycystic ovary syndrome. The data were processed by descriptive statistics. Results: 66, 97 % of patients answered to the treatment and 70, 00 % of patients who had normoandrogenic type answered correctly too. After the treatment 55, 50 % of patients continuous with ovary volume higher than 13 mL. Conclusions: the most important variation were to reduce blood levels of testosterone and to increase blood levels of progesterone. The therapeutic combination more used was hygienic-dietetic changes plus metformina.

Keywords : POLYCYSTIC OVARY SYNDROME [therapy]; PROGESTERONE [therapeutic use]; TREATMENT OUTCOME; INFERTILITY, FEMALE; EPIDEMIOLOGY, DESCRIPTIVE.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License